ArticleNature communications2025

Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.

Jeffrey M Clarke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.